31 results about "Clinical pregnancy" patented technology

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and / or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo has reached the blastocyst-stage.

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and / or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo has reached the blastocyst-stage.

The invention relates to the field of genetic diagnosis and human assisted reproduction, and more particularly relates to an embryo pre-implantation genetic diagnosis technique (PGD). According to the method provided by the invention, for patients suffering from chromosomal balanced translocation (including reciprocal translocation and Robertson translocation) and mates thereof, family haplotype linkage analysis is performed on the chromosomes of the embryos obtained by in vitro fertilization and the relatives of the translocation carrier, the embryos with chromosomal balanced translocation and the embryos with normal chromosomes can be rapidly, simply and accurately distinguished, and at the same time, the chromosome copy number variation of the embryo is screened, so that the clinical pregnancy rate is improved, the genetic transmission of the chromosomal balanced translocation to the next generation is timely blocked before embryo implantation, and thus the development and progress of the human assisted reproductive technology are promoted to a certain extent.

The invention belongs to the technical field of assisted reproduction, and particularly relates to a oocyte in-vitro maturity nutrient solution and a preparation method thereof. The oocyte in vitro manturation culture medium is based on commercialized tissue nutrient solution TCM199, and accurately added commercialized constituents comprise 0.075-0.10 IU / ml FSH and 0.5-0.8 IU / ml HCG, 0.1-0.2 microgram / ml 17 beta-estradiol, and human commercialized replaced serum or human albumin with the volume percent being of 10-20 percent. The oocyte in-vitro maturity nutrient solution is stable in constituents and quality, can be industrially produced. By adding commercialized human replaced serum and serum albumin, improving the concentration of the estradiol, FSH and HCG in the culture medium and simulating in-vivo mature environment in human oocyte, a good clinical effect is obtained, the in vitro maturity rate of oocyte reaches 72.08 percent, and the clinical pregnancy rate reaches 23.71 percent.

The invention provides an application of enhancing antioxidation of an oocyte cultured in vitro by a Peroxiredoxin 4 protein. The maturing rate of the immature oocyte cultured in vitro can be improvedby improving the resistance of particle cells in oxidative stress and improving the antioxidation of the oocyte. Aging of the oocyte is also delayed through an antioxidant stress mechanism in the cell, and the fertility rate and the clinical pregnancy rate of the oocyte in an assisted breeding process are improved.

The invention discloses a method for improving the test-tube baby clinical outcome by selecting an embryo with good development potential. The method comprises five steps that the transplanting embryo with good development potential is selected mainly according to IL-8 in an embryo culture solution before the transplanting; concretely, a liquid phase chip high-flux protein analysis technology is used for detecting the content of IL-8 in a sample; an IL-8 positive embryo in the culture solution is selected to be combined with a morphology evaluation method to perform transplantation; the IL-8 positive embryo in the culture solution before the transplantation is used for being combined with the morphological high-quality embryo to perform transplantation; the pregnancy rate can be improved by more than 8 percent, and can reach 60.76 percent; compared with the existing transplantation method for selecting the embryo singly by a morphology method, the method provided by the invention has the advantages that the pregnancy rate can be improved by more than 8 percent to 12 percent. When the method is combined with the existing morphology method for selecting high-quality embryo; or the high-quality embryo and the ordinary embryo are transplanted to an in vitro fertilization person, the embryo planting rate can also be improved; the baby live birth number is increased; the patient clinic pregnancy rate is improved; the abortion rate is reduced.

The invention provides a method for judging a cell state in a body liquid environment based on a liquid-phase chip technology. A biological marker of a follicular fluid is analyzed by using the liquid-phase chip technology, so as to judge the quality of forming an embryo by an ovum from the same follicular of the follicular fluid; good-quality embryo selection is determined by combining with a morphological analysis. With the adoption of the method provided by the invention, the clinical pregnancy rate and the embryo implantation rate of IVF (In-Vitro Fertilization) can be improved by providing an objective indicator of the ovum quality, so as to improve the result of IVF therapy. A plurality of factor combinations for judging the ovum quality of the follicular fluid can be produced into a commercial liquid-phase chip kit which is used for assisting the reproduction technology.

The invention relates to a homogeneous immunoassay reagent kit for detecting beta human chorionic gonadotropin and a preparation method and application thereof. The homogeneous immunoassay reagent kitof the beta human chorionic gonadotropin obtained by the method provided by the invention has a wide range of signal values and reaches a quantitative test standard when used for analyzing in a photoexcited chemiluminescence immunoassay platform; the homogeneous immunoassay reagent kit is high in sensitivity and can be used for accurate in-vitro diagnosis of beta-hCG levels in serum or urine; thehomogeneous immunoassay reagent kit has good stability and high precision; and by analysis system optimizing (antibody dosage and buffer and the like), the analytical performance meets industry standards, and a reference is provided for clinical pregnancy diagnosis and dynamic monitoring of hydatidiform moles and therapeutic effect of chorio-epithelioma.

The invention discloses an auxiliary activation device for a frozen embryo, and relates to the technical field of medical equipment. The device comprises a shell internally provided with a containingcavity; the frozen embryo contained in a straw is arranged in the containing cavity; a light source is arranged on the inner wall surface of the shell; and the light source emits low-intensity light to the frozen embryo. The auxiliary activation device for the frozen embryo can be used as an auxiliary activation means for the frozen embryo, the survival rate of frozen embryo recovery is increased,and therefore the clinical pregnancy rate of frozen embryo recovery is increased.

The invention discloses a traditional Chinese medicine composite for improving endometrium receptivity, and a preparation method of the traditional Chinese medicine composite. The composite is prepared from the following raw materials: human placenta, rhizoma polygonati and salvia miltiorrhiza. The invention further provides the preparation method of the traditional Chinese medicine composite for improving the endometrium receptivity. The composite increases an assisted reproduction medical clinical pregnancy rate, and has effects of tonifying a kidney, replenishing essence, nourishing blood, and promoting blood circulation for regulating menstruation. The endometrium receptivity after ovulation induction treatment can be improved effectively by adjusting generation of an endometrium blood vessel in an implantation window stage, and the clinical pregnancy rate can be increased, so that repeated treatment caused by repeated test tube baby failure is reduced, and psychological, physical and economic burdens of a patient are alleviated.

An assisted reproductive technology library management system based on the Internet of Things comprises a reproductive center client, a supplier terminal and a logistics terminal which are connected together through the computer or mobile phone Internet of Things. According to the system, the system can be connected with a hospital information system, a supplier warehouse management system and a cold-chain logistics system, so that the quality of the embryo culture medium is controlled and supervised from all links, an important role is played in improving the embryo culture quality and the clinical pregnancy rate, and the system can be widely applied to all reproductive medical centers in China.

The invention provides a biomarker and a medicament for recurrent implantation failure. The biomarker comprises one or more of pathway related genes with the G0 annotation being GO: 0030286, GO: 0003777, GO: 0007018, GO: 0016887, GO: 0005874, GO: 0005858, GO: 0060285 and GO: 0005871, or / and the KEGG annotation being hsa05016, and one or more of pathway related genes with the G0 annotation being GO: 0030286, GO: 0003777, GO: 0007018, GO: 0016887, GO: 0005874, GO: 0005858, GO: 0060285 and GO: The biomarkers are used for characterizing, diagnosing or classifying'subclinical hypopituitary hypofunction 'patients with repeated implantation failure and predicting the therapeutic reactivity of the patients with repeated implantation failure to luteal support therapy; the invention also provides a medicament for repeated implantation failure, a lutein therapy medicament and a luteinizing activity related medicament, the lutein therapy medicament is a medicament for regulating estrogen and / or progestational hormone, and the luteinizing activity related medicament is a medicament for regulating the estrogen and / or progestational hormone after embryo implantation by applying human chorionic gonadotropin. The repeated implantation failure object has the characteristics that (1) clinical pregnancy is not observed in continuous three or more times of high-quality embryo transplantation, (2) the pathogenesis of RIF is indefinite, and (3) the blood luteinizing hormone level is less than or equal to 5IU / L on the second day (D2 day) after ovulation.

The invention discloses a Chinese herbal compound composition capable of treating anovulatory infertility and application thereof. The Chinese herbal compound composition is prepared from 1-12 parts of radix rehmanniae preparata, 1-10 parts of roasted rhizoma atractylodis macrocephalae, 1-7.5 parts of poria cocos, 1-6 parts of fructus corni, 1-6 parts of radix salviae miltiorrhizae, 1-9 parts of fructus rubi, 1-6 parts of rhizoma dioscoreae, 1-9 parts of radix glehniae, 1-6 parts of semen cuscutae, 1-7.5 parts of fructus rosae laevigatae and 1-6 parts of semen ziziphi spinosae. The Chinese herbal compound composition achieves a good treatment effect when applied to the clinical treatment of anovulatory infertility under the guidance of traditional Chinese medicine theory. Clinical observation results show that the Chinese herbal compound composition mostly promotes the ovulation of single dominant follicles, has little influence on the endometrium and makes endometrium development synchronized with follicle development, so that a high periodic ovulation rate and clinical pregnancy rate are obtained, and a good treatment effect on anovulatory infertility is achieved. Besides, the Chinese herbal compound composition is very low in toxic or side effect and safe and reliable in clinical medication.

The invention discloses an embryo automatic liquid change culture dish including at least one group of culture unit; the culture unit includes a liquid injection pool, a culture pool and a waste liquid chamber which communicate with each other in turn; the upper part of the liquid injection pool communicates with a liquid inlet channel, and the bottom of the liquid injection pool communicates withthe bottom of the culture pool through an overflow channel; the bottom of the culture pool is provided with at least one embryo micropore, and the bottom of the embryo micropore communicates with thewaste liquid cavity through a waste liquid flow channel. The embryo automatic liquid change culture dish can realize complete liquid exchange and effectively meet material requirements required in each development stage of an embryo; through automatic liquid exchange, the damage of repeated manual intervention operation to an embryo culture environment and the damage of the embryo are avoided, the stability of the embryo culture and the quality of a blastocyst can be improved, and the clinical pregnancy rate and the live yield are effectively increased.

The invention provides a traditional Chinese medicinal composition for treating hypothyroidism. The traditional Chinese medicinal composition is prepared from the following raw medicinal materials in parts by weight: 100-300 parts of stir-baked fructus gardeniae, 200-500 parts of oriental wormwood, 150-450 parts of prepared rehmannia root, 200-500 parts of raw rehmannia root, 150-450 parts of bighead atractylodes rhizome, 100-300 parts of mulberry leaf and 100-300 parts of lophatherum gracile. The traditional Chinese medicinal composition is supported by the solid classic theory of gynecology of traditional Chinese medicine, is reasonable in component composition and exact in curative effect, can be used for remarkably increasing the clinical pregnancy rate, does not have toxic or side effect, is safe to take and easy to control quality due to few medicinal materials at low cost, and can be applied to preparation of the traditional Chinese medicinal composition for treating sub-clinical hypothyroidism in in-vitro fertilization-embryo transplantation.

The invention relates to a kidney-tonifying fetus-developing traditional Chinese medicine composition and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material herbs: radix rehmanniae praeparata, radix astragali, fructus ligustri lucidi, radix ophiopogonis, radix paeoniae alba, radix codonopsis, rhizoma cyperi, semen cuscutae, angelica sinensis, fructus psoraleae, salviae miltiorrhizae and radix glycyrrhizae. The invention further provides application of the traditional Chinese medicine composition. The kidney-tonifying fetus-developing traditional Chinese medicine composition has the following advantages: the estrogen level of a patient with kidney qi deficiency in the decorporation stage is remarkably improved, and more retrieved oocytes, fertilized oocytes, developed embryos and high-quality embryos are obtained; expression of endometrial vascular endothelial growth factors is remarkably improved, endometrial blood flow parameters PI and RI of the patient with kidney qi deficiency are reduced, blood perfusion is increased, and further, the endometrial recepyivity of the patient isimproved; and the embryo transfer rate can be remarkably increased, and the kidney-tonifying fetus-developing traditional Chinese medicine composition tends to increase the clinical pregnancy rate, implantation rate and persistent pregnancy rate.

The invention provides a method for judging a cell state in a body liquid environment based on a liquid-phase chip technology. A biological marker of a follicular fluid is analyzed by using the liquid-phase chip technology, so as to judge the quality of forming an embryo by an ovum from the same follicular of the follicular fluid; good-quality embryo selection is determined by combining with a morphological analysis. With the adoption of the method provided by the invention, the clinical pregnancy rate and the embryo implantation rate of IVF (In-Vitro Fertilization) can be improved by providing an objective indicator of the ovum quality, so as to improve the result of IVF therapy. A plurality of factor combinations for judging the ovum quality of the follicular fluid can be produced into a commercial liquid-phase chip kit which is used for assisting the reproduction technology.

The invention relates to an application of a GM-CSF factor as a biomarker in screening assisted reproductive transplantation embryos and a method, the method takes the GM-CSF factor as the biomarker,and the concentration of the GM-CSF factor in a blastocyst culture solution of the embryos is in positive correlation with the transplantation success rate of the embryos. The successful transplantation means that the screened embryo can be pregnant after transplantation, and the pregnancy comprises HCG positive, clinical pregnancy and continuous pregnancy. The HCG positive is positive when a pregnancy marker HCG in serum or urine is detected in 11 days after transplantation. The clinical pregnancy refers to intrauterine pregnancy sacs found through vaginal ultrasound 30 days after transplantation, wherein the continuous pregnancy is that the pregnancy lasts for more than 3 months. The method can also be combined with morphological scoring, and the higher the concentration of the GM-CSF factor is, the higher the success rate of embryo transplantation with better morphological scoring quality is.

The invention relates to a sperm optimization device and a sperm optimization method used for horizontal intracytoplasmic single sperm injection. The sperm optimization device comprises a sperm optimization trough, the interior of the sperm optimization trough is divided into a sperm storage pool and a high-quality sperm pool by a clapboard, a sperm swimming channel is formed in the clapboard, thesperm swimming channel is communicated with the sperm storage pool and the high-quality sperm pool, and a constant temperature heating plate I and a constant temperature heating plate II are respectively arranged below the sperm storage pool and the high-quality sperm pool; according to the sperm optimization method, sperm with good activity swims from the sperm storage pool with low temperatureto the high-quality sperm pool with high temperature through the sperm swimming channel by utilizing the temperature difference between the sperm storage pool and the high-quality sperm pool. According to the invention, sperm obtain by a gradient centrifugation method can be further optimized, sperm with relatively good activity is selected, and the selected sperm is used for fertilization, so asto improve the fertilization rate of ICSI and the development ability of embryos after ICSI, and finally increase the clinical pregnancy rate.

The invention provides a traditional Chinese medicine composition for preventing ovarian hyperstimulation syndrome (OHSS). The traditional Chinese medicine composition is prepared from the following medicinal raw materials in parts by weight: 100-300 parts of poria cocos, 200-500 parts of coix seed, 150-450 parts of grifola, 200-500 parts of gordon euryale seed, 150-450 parts of caulis perllae, 100-300 parts of old pumpkin stalks and 100-300 parts of honey-fried licorice root. The traditional Chinese medicine composition is supported by solid Chinese medicine gynecology department classical theory and is reasonable in component ratio; the traditional Chinese medicine composition has a definite curative effect and no toxic or side effects, is capable of obviously reducing the occurrence rate of OHSS and obviously increasing the clinical pregnancy rate, and is safe to take. The herbal medicines in the traditional Chinese medicine composition are few, so that the quality control is easy, and meanwhile, the cost is low; the herbal medicines can be applied in preparation of the traditional Chinese medicine composition for preventing the OHSS in vitro fertilization and embryo transfer.

The invention relates to the field of genetic diagnosis and human assisted reproduction, and more particularly relates to an embryo pre-implantation genetic diagnosis technique (PGD). According to the method provided by the invention, for patients suffering from chromosomal balanced translocation (including reciprocal translocation and Robertson translocation) and mates thereof, family haplotype linkage analysis is performed on the chromosomes of the embryos obtained by in vitro fertilization and the relatives of the translocation carrier, the embryos with chromosomal balanced translocation and the embryos with normal chromosomes can be rapidly, simply and accurately distinguished, and at the same time, the chromosome copy number variation of the embryo is screened, so that the clinical pregnancy rate is improved, the genetic transmission of the chromosomal balanced translocation to the next generation is timely blocked before embryo implantation, and thus the development and progress of the human assisted reproductive technology are promoted to a certain extent.

The invention discloses a molecular marker miR-122. A nucleotide sequence of the molecular marker miR-122 is as shown in SEQ ID NO: 1. The invention also discloses a kit for male fertility diagnosis,a reagent for determining the expression quantity of the molecular marker miR-122 in seminal fluid, and a fertilization rate and a blastocyst formation rate are prompted through the expression quantity of the miR-122. By detecting the expression quantity of miR-122 in the seminal fluid, fertilization, embryonic development and clinical pregnancy conditions can be judged, a simple, convenient, easy-to-operate and high-sensitivity method is provided for male fertility judgment, and the method can be used as a new index for evaluating the male fertility.

The invention relates to the technical field of human assisted reproduction, in particular to a novel culture dish used for fertilization. The culture medium is a four-hole dish or an annular dish; a dish body of the culture dish comprises a bottom wall, a main side wall and an auxiliary side wall which are integrally formed; the main side wall and the auxiliary side wall are arranged on the bottom wall; the auxiliary side wall is positioned on an inner side of the main side wall; in the four-hole dish, a hole is formed in each of four corners on an inner side of the auxiliary side wall; in the annular dish, a middle hole is formed in the middle of the auxiliary side wall. Sperms added during fertilization are separated from an ovum by utilizing a bionic principle and good-quality sperms are enabled to swim to the periphery of the ovum for fertilization by utilizing a groove, so that the good-quality embryo rate and the clinical pregnancy rate of in-vitro fertilization can be increased.

The invention relates to a method for identifying a CNV microdeletion and microduplication syndrome diseased embryo and a normal embryo. The invention belongs to the field of genetic diagnosis and human assisted reproduction, and more particularly relates to a pre-implantation embryo detection technology (PGT). According to the method disclosed by the invention, family haplotype linkage analysis is carried out on a patient suffering from the CNV microdeletion and microduplication syndrome, a partner of the patient, an embryo after in-vitro insemination and chromosomes of relatives of the patient or fetal tissues suffering from the CNV microdeletion and microduplication syndrome; the method can quickly, simply, conveniently and accurately distinguish the diseased embryo carrying CNV from the normal embryo, and simultaneously screen the chromosome aneuploid of the embryo, thereby improving the clinical pregnancy rate, realizing the timely detection of the diseased embryo and the transplanted non-diseased embryo before embryo transplantation, preventing the birth of defective children, and improving the survival rate of the children. And the genetic transmission of the CNV microdeletion and microduplication syndrome disease to the next generation is timely blocked. The development and progress of a human assisted reproduction technology are promoted to a certain extent.

The present invention discloses an application of microbubble-combined ultrasound intervention in preparing a system for improving receptivity of thin-type endometrium. The microbubble-combined ultrasound intervention provided for the first time can enhance expressions of IGFBP-1 and VEGF in the endometrium, improve decidualization status and blood supply of the endometrium, and increase thicknessof the thin-type endometrium. The system expands use ranges of the microbubble-combined ultrasound and at the same time also provides a new direction for improving the receptivity of the thin-type endometrium; and besides, from results of animal experiments, the microbubble-combined ultrasound intervention can increase the thickness of the endometrium, reconstructs local blood supply and glands,has a relatively good effect, provides new methods and new ideas for clinical treatment of the thin-type endometrium, thus looks forward to increase the thickness of the endometrium through intrauterine infusion of ultrasound microbubbles, improves a clinical pregnancy rate of patients with the thin-type endometrium and solves one of two key factors for successful embryo implantation.

The invention provides a traditional Chinese medicinal composition for treating hypothyroidism. The traditional Chinese medicinal composition is prepared from the following raw medicinal materials in parts by weight: 100-300 parts of stir-baked fructus gardeniae, 200-500 parts of oriental wormwood, 150-450 parts of prepared rehmannia root, 200-500 parts of raw rehmannia root, 150-450 parts of bighead atractylodes rhizome, 100-300 parts of mulberry leaf and 100-300 parts of lophatherum gracile. The traditional Chinese medicinal composition is supported by the solid classic theory of gynecology of traditional Chinese medicine, is reasonable in component composition and exact in curative effect, can be used for remarkably increasing the clinical pregnancy rate, does not have toxic or side effect, is safe to take and easy to control quality due to few medicinal materials at low cost, and can be applied to preparation of the traditional Chinese medicinal composition for treating sub-clinical hypothyroidism in in-vitro fertilization-embryo transplantation.

The invention discloses a molecular marker miR‑122, the nucleotide sequence of which is shown in SEQ ID NO:1. Also disclosed is a diagnostic kit for male fertility, a reagent for determining the expression level of the molecular marker miR-122 in semen, through which the expression level of miR-122 indicates the fertilization rate and blastocyst formation rate . The present invention can judge the fertilization, embryo development and clinical pregnancy by detecting the expression of miR‑122 in semen, and provides a simple and easy-to-operate method with high sensitivity for judging male fertility, which can be used as a new method for evaluating male fertility. index.

The invention belongs to the technical field of assisted reproduction, and particularly relates to a oocyte in-vitro maturity nutrient solution and a preparation method thereof. The oocyte in vitro manturation culture medium is based on commercialized tissue nutrient solution TCM199, and accurately added commercialized constituents comprise 0.075-0.10 IU / ml FSH and 0.5-0.8 IU / ml HCG, 0.1-0.2 microgram / ml 17 beta-estradiol, and human commercialized replaced serum or human albumin with the volume percent being of 10-20 percent. The oocyte in-vitro maturity nutrient solution is stable in constituents and quality, can be industrially produced. By adding commercialized human replaced serum and serum albumin, improving the concentration of the estradiol, FSH and HCG in the culture medium and simulating in-vivo mature environment in human oocyte, a good clinical effect is obtained, the in vitro maturity rate of oocyte reaches 72.08 percent, and the clinical pregnancy rate reaches 23.71 percent.